Metabolic syndrome and cardiovascular disease: Epidemiology, pathophysiology, and therapeutic considerations

Risk Factors in Coronary Artery Disease

Volumn , Issue , 2006, Pages 1-34

  Deedwania, Prakash C ^a   Volkova, Natalia ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250163387     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (154)

1. Reaven GM. Banting Lecture1988: role of insulin resistance in human disease. Diabetes 1988; 37:1595–1607.
2. Park Y, Shankuan Z, Palaniappan L, et al. The metabolic syndrome. Arch Intern Med 2003; 163:427–436.
3. Fagan TC, Deedwania PC. The cardiovascular dysmetabolic syndrome. Am J Med 1998; 105:S77–S82.
4. Caprio S. Insulin resistance in childhood obesity. J Pediat Endocrinol Metab 2002; 15:487–492.
5. Goran MI, Gower BA. Abdominal obesity and cardiovascular risk in children. Coron Artery Dis 1998; 9:427–436.
6. Weiss R, Dziura J, Burgert T, et al. Obesity and metabolic syndrome in children adolescents. N Engl J Med 2004; 350:2362–2374.
7. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346:802–810.
8. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986–1998. JAMA 2001; 286:2845-2848.
9. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among U.S. Adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356–359.
10. Kraja AT, Hunt SC, Pankow JS, et al. An evaluation of the metabolic syndrome in HyperGen Study. Nutr Metab 2005; 2:1–9.
11. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabet Care 2001; 24:683–689.
12. Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003; 289:187–193.
13. Cook S, Witzman M, Auinger P, et al. Prevalence of a metabolic syndrome phenotype in adolescents. Arch Pediat Adolesc Med 2003; 157:821–827.
14. Malina R, Katzarzyk T. Validity of the body mass index as an indicator of the risk and presence of overweight in adolescents. Am J Clin Nutr 1999; 70:131S–136S.
15. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovasdculalr disease mortality in middle-aged men. JAMA2002; 25:2709–2716.
16. National diabetes Data Group Diabetes in America., 2nd ed. Washington, DC: National Institues of Health, 1995.
17. Trevisan M, Liu J, Bahsas FB, et al. Syndrome X and mortality: a population-based study: risk factor and life expectancy research group. Am J Epidemiol 1998; 148:958–966.
18. Wilson PW, Kannel WB, Silberschatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159:1104–1109.
19. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and it’s relation to all-cause and cardiovascular morality in nondiabetic European men and women. Arch Intern Med 2004; 164:1066–1076.
20. Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians. The Strong Heart Study. Diabetes Care 2003; 26:861–867.
21. Alexander CM, Landsman PB, Teutsch S, et al. NCEP-defind metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 or older. Diabetes 2003; 52:1210–1214.
22. Ninomiya JK, L’Itaien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109:42–46.
23. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus metabolic syndrome in cardiovascular risk in women. A report from the Women’s Ischemia Syndrome Study Evaluation (WISE) study. Ciruclation 2004; 109:706–713.
24. Lawlor DA, Ebrahim S, Smith DG. The metabolic syndrome and coronary heart disease in older women: findings from the British Women’s Heart and Health Study. Diabet Med 2004; 21:906–913.
25. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference and health risk. Arch Intern Med 2002; 162:2074–2079.
26. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome. Criculation 2004; 109:433–438.
27. Frayn KN. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001; 60:375–380.
28. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941–946.
29. Combs TP, Berg AH, Obici T, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp 30. J Clin Invest 2002; 108:1875–1881.
30. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of novel, adioposespecific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20:1595–1599.
31. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrionol Metab 2001; 86:1930–1935.
32. Yamauchi T, Kamon J, Minakoshi Y, et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP activated protein kinase. Nat Med 2002; 8:1288–1295.
33. Stephan N, Vozarons B, Funahashi T, et al. Plasma adiponectin is associated with skeletal muscle insulin receptor tyrosin phosphorylation, and low plasma concentrations precedes a decrease in whole body insulin sensitivity in humans. Diabetes 2002; 51:564–569.
34. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the pima Indian population. Lancet 2002; 360:57–58.
35. Yang W-S, Lee W-J, Funahashi T, et al. Weight reduction increases plasma levels of adipose-derived antiinflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86:2815–2819.
36. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730–1737.
37. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7:947–953.
38. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98:2005–2010.
39. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp 30. J Clin Invest 2001; 108:1875–1881.
40. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361:226–228.
41. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP 30. Nat Med 2002; 8:731–737.
42. Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52:942–947.
43. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107:671–674.
44. Krakoff J, Funahashi T, Stehouwer CD, et al. Infammatory markers, adiponcetin, and risk of type 2 diabetes in Pima Indian. Diabet Care 2003; 26:1745–1751.
45. Matsubara M, Namioka K, Katayose S. Decreased plams adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol 2003; 148:657–662.
46. Kern PA, Di Gregorio GB, Lu T, et al. Adiponcetin expression from human adipose tissue: relation to obesity, insulin resisitanc, and tumor necrosis factor-alpha expression. Diabetes 2003; 52:1779–1785.
47. Ouchi N, Hihara S, Arita Y, et al. Adipocyte derived plasma protein, adiponcectin, suppresses lipid accumulation and class a scavenger receptor expression in human monocyte-derived macrophages. Circulation 2002; 103:1057–1063.
48. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponcetin acts as platelet-derived growth factor—BB-binding protein and regulates growth factor—induced common postereceptor signal in vascular smooth muscle cell. Circulation 2002; 105:2893–2898.
49. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponcectin, adheres to injured vascular walls. Horm Metab Res 2000; 32:47–50.
50. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85–89.
51. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13:134–141.
52. Okamoto Y, Kihara S, Ouchi N, et al. Adioncetin reduces atherosclerosis in apolipoptroein E-deficient mice. Circulation 2002; 106:2767–2770.
53. Yamauchi T, Kamon J, Waki H, et al. Globular adiopnectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278:2461–2468.
54. Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004; 88:63–82.
55. Klein S, Fontana L, Young L, et al. Absence of an effect of liposcutionon insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350:2549–2557.
56. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation and American Heart Association. Circulation 2004; 110:227–239.
57. Tuomilehto J, Lindstrom J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among sunjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343–1350.
58. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393–403.
59. Brooks GA, Butte NF, Rand WM, et al. Chronicle of the Institute of Medicine physical activity recommendation: how a physical activity recommendation came to be among dietary recommendations. Am J Clin Nutr 2004; 79:921S–930S.
60. Didangelos T, Thanopoulou A, Bousboulas, et al. The orlistat and cardiovascular risk profile inpatient swith metabolic syndrome and type 2 diabetes (ORLICARDIA) study. Curr Med Res Opin 2004; 20:1393–1401.
61. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106:286–288.
62. The DECODE Study Group on Behalf of the European Diabetes Epidemiology Group. Current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26:688–696.
63. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The Stop-NIDDM trial. JAMA 2003; 290:486–494.
64. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11:183–191.
65. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesityinduced insulin resistance. Nat Med 2005; 11:191–198.
66. Coulston AM, Peragallo-Dittko V. Insulin resistance syndrome: a potent culprit in cardiovascular disease. J Am Diet Assos 2004; 104:176–179.
67. Ducimentiere P, Eschwege E, Papoz L, et al. Relationship of plasma insulin level to the incidence of myocardial infarction and coronary heart disease. Diabetologia 1980; 19:205–210.
68. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in healthy population: The Paris Prospective Study, 15-year follow-up. Diabetologia 1991; 34:356–361.
69. Desperés J-P, Lamarche B, Mauriege P, et al. Hyperinsulinemia is an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952–957.
70. Howard BV, Gray RS. Insulin resistance and cardiovascular disease. Diabetes Annu 1999:305–316.
71. Bonora E, Formentine G, Calcaterra F. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care 2002; 25:1135–1141.
72. Salonaa V, Riley W, Kaark JD, et al. Non-insulin dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness index the ARIC study. Circulation 1995; 91:1432–1443.
73. Suzuki M, Shinozaki K, Kanazawa A, et al. Insulin resistance as an independent risk for carotid wall thickening. Hypetension 1996; 28:593–598.
74. Shinozaki K, Naritomi H, Shimizu T, et al. Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke. Stroke 1996; 27:37–43.
75. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106–1118.
76. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39:188–196.
77. Assmann G, Schulte H. The Prospective Cardiovascular Munster study: prevalence and hyperlipidaemia in persons with hypertension and/or diabetes mellitus and relationship to coronary heart disease. Am Heart J 1988; 116:1713–1724.
78. Reynisdottir S, Angelin B, Landgin D, et al. Adipose tissue lipoprotiein lipase and hormone-sensitive lipase.Contrasting findgidng in familial combined hyperliipidemia and insulin resistance syndrome. Arterioscler Thromb Vasc Biol 1997; 17:2287–2292.
79. Davy BM, Melby LC. The effect of fiber-rich carbohydrates on features of syndrome, X. J Am Diet Assoc 2003; 103:86–96.
80. Eckel RH. Familial Combined hyperlipidemia and insulin resistance: distant relatives linked by intra-abdominal fat? Arterioscler Thromb Vasc Biol 2001; 21:469–470.
81. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70:3H–9H.
82. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response ot simvastatin therapy in 4 S. Circulation 2001; 18:3046–3051.
83. Mamo JC, Yu KC, Elsegood CL, et al. Is atherosclerosis exclusively a postprandial phenomenon? Clin Exp Pharmacol Physiol 1997; 24:288–293.
84. Sowers JR. Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolics syndrome. Am J Cardiol 2003; 91:14B–22B.
85. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adulat Treatment Panel III guidelines. Circulation 2004; 110:227–239.
86. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498–511.
87. Deedwania PS, Hunnighake DB, Bays HE, et al. Effects of Rosuvastatin, Atorvastatin, Simvastatin, and Pravastatin on atherogenic dyslipidemia in patient with characteristics of the Metabolic Syndrome. Am J Cardiol 2005; 95:360–366.
88. Cziraky MJ. Mangement of dyslipidemia in patients with metabolic syndrome. J Am Pharm Assoc 2004; 44:478–488.
89. Chapman MJ, Assmann G, Fruchart J-C, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a positon paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20:1253–1268.
90. Dimons L, Tonkon M, Masana L, et al. Effects of ezetimibe added to on-going stain therapy on tlipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004; 20:1437–1445.
91. Ferrannini E, Buzzigoli C, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317:350–357.
92. Shen DC, Shieh SM, Wu DA, et al. Resistance to insulin stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Meat 1998; 66:580–583.
93. Gress TW, Niet FJ, Shahar E, et al. Hypertesion and atnihypertesiver therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in community study. N Engl J Med 1987; 342:905–912.
94. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000; 342:969–970.
95. Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and arherosclrosis. J Lab Clin Med 1994; 123:647–652.
96. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and sympathetic adrenal system. N Engl J Med 1996; 334:374–381.
97. Nolan JJ, Ludvik B, Baloga J, et al. Mechanisms of the kinetic defect in insulin action in obesity and NIDDDM. Diabetes 1997; 46:494–500.
98. Sowers JR. Insulin and insulin-like growth factor in noral and pathoplogical cardiovascular physiology. Hypertension 1997; 29:691–699.
99. Sowers JR. Effects on insulin and IGF-1 on vscular smooth muscle glucose and cation metabolism. Diabetes 1996; 45:S47–S51.
100. Ren J, Samson WK, Sowers JR. Insulin -like growth gactor 1 as a cardiac hormone: physiological and pahtyophysiological implications inheart disease. J Mol Cell Cardiol 1999; 31:2049–2061.
101. Wang HD, Xu S, Johns DG, et al. Role of NADH oxidase in the vascular hypertrophic and oxidative stress responses to angiotensin II in mice. Circ Res 2001; 88:947–953.
102. Huerta MG, Nadler JL. Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. Curr Diab Rep 2002; 2:396–402.
103. Griendling KK, Sorescu D, Ushio-Fukai M. Nad(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86:494–501.
104. Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002; 20:346–348.
105. Kalinowksi L, Matjie T, Chabelsky E, et al. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitci oxide release. Hypertension 2002; 40:521–527.
106. Katovidh MJ, Pachori A. Effects of inhibition of the rennin-angiotensin system of the cardiovascular actions of insulin. Diabet Obes Metab 2002; 2:3–14.
107. Grunfeld B, Balzareti H, Romo H, et al. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994; 23:112–115.
108. Beatty OL, Harper R, Sheridan B. Insuln resistance in offspring of hypertensive parents. BMJ 1993; 3017:92–96.
109. Taittonen L, Uhari M, Nuutinen M, et al. Insulin and blood pressure among healthy children: cardiovasular risk in young Finns. Am J Hypertens 1996; 9:193–199.
110. Hooper L, Barlett C, Davey SG, et al. Advice to reduce dietary salt for prevention of cardiovascular disease. Cochrane Database Syst Rev 2004; CD003656.
111. Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure: subfourp analysis of the DASH-sodium trial. Ann Intern Med 2001; 135:1019–1028.
112. Katovidh MJ, Pachori A. Effects of inhibition of the rennin-angiotensin system of the cardiovascular actions of insulin. Diabetes Obes Metab 2002; 2:3–14.
113. Hanson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The captorpril prevention project randomized trial. Lancet 1999; 353:611–616.
114. Yusuf S, Sleight P, Pgue J, et al. Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patient’s.The HeartOutcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145–153.
115. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovasuclar morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study: a randomized trial against atenolol. Lancet 2002; 359:995–1003.
116. Heart Outcomes Prevention Evaluation (HOPE) study Investigators. Effects of ramipril on cardiovascular and mircovascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253–259.
117. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and caridovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869.
118. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotecive effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 354:851–860.
119. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–2997.
120. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating form adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972–978.
121. Pradhan AD, Manson JE, Rifai NC, et al. C-reactive protein, interleukin 6, and risk of developing diabetes mellitud. JAMA 2001; 286:327–334.
122. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow up of 14 719 initially healthy American women. Circulation 2003; 107:391–397.
123. Festa A, D’Agostino R, Jr., Howard G, et al. Chronic subclinical inflammation as part of ithe insulin resistance syndrome: the Insulin Resistance Aterhosclerosis Study (IRAS). Circulation 2000; 102:42–47.
124. Chen YQ, Su M, Walia RR, et al. Sp1 sties mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 1998; 273:8225–8231.
125. Arand SS, Qilong Y, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108:420–425.
126. Kohler HP, Grant PJ. Mechanisms of disease: plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792–1801.
127. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associates eith endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 1996; 97:2601–2610.
128. Higashi Y, Oshima T, Sasaki N, et al. Relationship between isnuin resistance and endothelium-dependent vascular relaxation inpatients with essential hypertension. Hypertension 1997; 29:280–285.
129. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101:1780–1784.
130. Chen NG, Holmes M, Reaven GM. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab 1999; 84:3485–3489.
131. Enderle MD, Benda N, Schmuelling RM, et al. Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects. Diabetes Care 1998; 21:271–277.
132. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. its mechanism, measurment, and significance. J Am Coll Cardiol 1999; 34:146–154.
133. Chan NN, Chan CN. Asymmetric dimethylarginine (ADMA): a potent link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetolgia 2002; 45:1609–1616.
134. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87:432–438.
135. Ridker RM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836–843.
136. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged: results from MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg cohort study. Circulation 1999; 99:237–242.
137. Forouhi MG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans ans South Asians. Int J Obes Relat Metab Disord 2001; 25:1327–1331.
138. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50:2384–2389.
139. Han ATS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation ot the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25:2016–2020.
140. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414–419.
141. Festa A, D’Agostino R, Jr., Tracy RP, et al. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51:1131–1137.
142. Pearson TA, Blair SN, Daniels SR, et al. American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular disease. American Hear Association Science Advisory and Coordinating Committee. Circulation 2003; 107:499–511.
143. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow up of 14 719 initially healthy American women. Circulation 2003; 107:391–397.
144. Feldman M, Jialal I, Devaraj S, et al. Effects of low-dose aspirin on serum C-reactive protein and throboxane B2 concentrations:A placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001; 37:2036–2041.
145. Agrawal B, Berger A, Wolf K, et al. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14:223–228.
146. Dinneen S, Gerstein H. The association of microabuminuria and mortality in noninsulin- dependent diabetes mellitus: A systematic overview of the literature. Arch Intern Med. 1997; 157:1413–1418.
147. Lydakis C, Lip G. Microalbuminuria and cardiovascular risk. QJM 1998; 91:381–391.
148. Miettinen H, Haffner SM, Lehto S, et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in non-diabetic and non-insulin dependent diabetic subjects. Stroke 1996; 27:2033–2039.
149. Culleton BF, Larson MG, Kannel WB, et al. Serumuric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131:7–13.
150. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. JAMA 2000; 283:2404–2410.
151. Verdecchia P, Schillaci G, Reboldi GP, et al. Relation between serum uric acid and cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36:1072.
152. Doelle GC. The clinical picture of metabolic syndrome: an update on this complex of conditions and risk factors. Postgrad Med 2004; 116:30–38.
153. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21:697–738.
154. Deedwania PC. Metabolic syndrome and vascular disease. Is nature or nurture leading the new epidemic of cardiovascular disease. Circulation 2004; 109:2–4.